$DRRX News Article - DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(TM) 2020
https://marketwirenews.com/news-releases/dure...31832.html